KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Edwards Lifesciences (EW) Cost of Revenue (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Cost of Revenue data on record, last reported at $343.0 million in Q4 2025.

  • For Q4 2025, Cost of Revenue rose 17.39% year-over-year to $343.0 million; the TTM value through Dec 2025 reached $1.3 billion, up 19.39%, while the annual FY2025 figure was $1.3 billion, 19.39% up from the prior year.
  • Cost of Revenue reached $343.0 million in Q4 2025 per EW's latest filing, down from $345.2 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $345.2 million in Q3 2025 and bottomed at -$98.8 million in Q4 2022.
  • Average Cost of Revenue over 5 years is $270.1 million, with a median of $296.3 million recorded in 2021.
  • Peak YoY movement for Cost of Revenue: crashed 131.92% in 2022, then soared 428.39% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $309.5 million in 2021, then plummeted by 131.92% to -$98.8 million in 2022, then surged by 155.97% to $55.3 million in 2023, then skyrocketed by 428.39% to $292.2 million in 2024, then rose by 17.39% to $343.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $343.0 million in Q4 2025, $345.2 million in Q3 2025, and $344.4 million in Q2 2025.